ResMed Inc (R1MD34) Fair Value & Analysis
Healthcare · BR · Market cap R$151B
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 11 days ago
Fair value updated Jun 24, 2026 — revised from R$42.64 to R$41.40 (−2.9%) since Jun 23, 2026. Share price −5.6% over the past month.
Price vs Fair Value (12 months)
12‑month range R$242.75 – R$394.84 · fair‑value band R$30.85 – R$55.43 · the R$245.50 price screens above the R$41.40 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
ResMed Inc (R1MD34) currently trades at R$245.50, while our model-based Fair Value estimate is R$41.40 — implying the stock looks roughly 83.1% overvalued today. We read business quality at 59/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, ResMed Inc generated revenue of R$5.5B at a net margin of 27.4%. Revenue grew 10.8% year over year. It earns a return on equity of 25.3%. Net debt stands at R$469M. Fundamentals as of Jun 24, 2026
Our scenario range runs from R$30.85 (bear case) to R$55.43 (bull case); at R$245.50, the current price sits above that range. The share trades about 38% below its 52-week high and 1% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -34% fair-value upside — at -83%, R1MD34 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, …
Revenue & earnings trend
FY2022 – FY2025 · reported fiscal years
ResMed Inc reported revenue of R$5.1B in FY2025 versus R$3.6B in FY2022, a compound +12.9%/yr. Reported net income was R$1.4B in FY2025, compounding +21.6%/yr from FY2022.
Is R1MD34 fairly valued? → Check now
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $412.02 | $165.35 | -60% |
| EssilorLuxottica Société anonyme ESLOF | $190.25 | $125.65 | -34% |
| HOYA Corporation HOCPY | $168.16 | $96.16 | -43% |
| Medline Inc MDLN | $36.54 | $30.66 | -16% |
| Becton, Dickinson and Company BDX | $140.71 | $104.17 | -26% |
| Alcon Inc ALC | $65.18 | $44.21 | -32% |
| West Pharmaceutical Services, Inc WST | $314.50 | $120.69 | -62% |
| Terumo Corporation TRUMF | $14.62 | $12.65 | -13% |
| Straumann Holding SAUHY | $13.07 | $5.51 | -58% |
| Sartorius Stedim Biotech S.A DIM | €178.10 | €34.72 | -81% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is ResMed Inc (R1MD34) undervalued?
What is the fair value of R1MD34?
What is the quality score of R1MD34?
What is the revenue of ResMed Inc (R1MD34)?
What is the net profit margin of R1MD34?
Does ResMed Inc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.